Statement of Changes in Beneficial Ownership (4)
2021年2月13日 - 7:32AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Lee Catherine Chai-zon |
2. Issuer Name and Ticker or Trading Symbol
Metacrine, Inc.
[
MTCR
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP, Gen. Counsel & Secretary |
(Last)
(First)
(Middle)
C/O METACRINE, INC., 3985 SORRENTO VALLEY BLVD.,SUITE C |
3. Date of Earliest Transaction
(MM/DD/YYYY)
2/10/2021 |
(Street)
SAN DIEGO, CA 92121
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | $10.09 | 2/10/2021 | | A | | 65000 | | (1) | 2/9/2031 | Common Stock | 65000 | $0.00 | 65000 | D | |
Explanation of Responses: |
(1) | 25% of the shares subject to the option shall vest on the one year anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter until fully vested on February 10, 2025. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Lee Catherine Chai-zon C/O METACRINE, INC. 3985 SORRENTO VALLEY BLVD.,SUITE C SAN DIEGO, CA 92121 |
|
| EVP, Gen. Counsel & Secretary |
|
Signatures
|
/s/ Catherine C. Lee | | 2/12/2021 |
**Signature of Reporting Person | Date |
Metacrine (NASDAQ:MTCR)
過去 株価チャート
から 9 2024 まで 10 2024
Metacrine (NASDAQ:MTCR)
過去 株価チャート
から 10 2023 まで 10 2024
Real-Time news about Metacrine Inc (ナスダック市場): 0 recent articles
その他のMetacrine, Inc.ニュース記事